ASCO 2022 | PARADIGM: panitumumab superior to bevacizumab as 1L treatment of patients with RAS WT mCRC

Takayuki Yoshino, MD, PhD , National Cancer Center Hospital, Chiba, Japan, shares results of the Phase III PARADIGM trial (NCT02394795) investigating anti-EGFR panitumumab antibody plus mFOLFOX6 versus the anti-VEGFR bevacizumab antibody plus mFOLFOX6 as first-line treatment in patients with left-sided RAS wild-type metastatic colorectal cancer (mCRC). The primary endpoint of the PARADIM trial was overall-survival (OS) and secondary endpoints included progression-free survival (PFS), response rate (RR) and duration of response (DOR). This Phase III study demonstrated a superior OS rate with panitumumab plus mFOLFOX6 compared to bevacizumab plus mFOLFOX6. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.